Edwards to launch Sapien XT valve in China in 2013
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences intends to launch its Sapien XT transcatheter aortic valve in China in 2013. The first implants of Sapien XT in Chinese patients were performed last month, the Irvine, California-based company said, as special access cases at the Second Military Medical University, under a joint educational and training programme on transcatheter aortic valve implantation between the university and Edwards. The Sapien XT valve was approved for sale in Europe in March 2010 (www.clinica.co.uk, 3 March 2010). It is not yet approved in the US, Japan or China.
You may also be interested in...
Normality Reasserts Itself For Biotech IPOs
The highs of the COVID-19 era, and the lows that supplanted it, are beginning to fade.
MRM Health Pulls A Pouchitis Hit Out Of The Bag
The mid-stage success is encouraging, but taking on Takeda won’t be easy.
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.